Brind.

Biomea Fusion reported that its next-generation GLP-1 RA candidate, BMF-650, combined with icovamenib, drove superior glycemic control.

3 reports, 2 independent Updated Aug 1
Gone quiet
Reports
3
Developments
3
Repetition
33%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 2 outlets

Biomea Fusion reported that its next-generation GLP-1 RA candidate, BMF-650, combined with icovamenib, drove superior glycemic control.

How it developed

Newest first. Tap a step to see who reported it.
  1. Biomea Fusion presented new clinical data on its BMF-650/icovamenib combination at the ADA conference.Sub-event
  2. Biomea Fusion's BMF-650 and icovamenib showed superior glycemic control when combined with Semaglutide.1 source
  3. Biomea Fusion undergoes management changes, appointing a new board member and accepting a resignation.1 source

Coverage

Newest first; wire copies grouped
  • manilatimes.net
  • GlobeNewswireBiomea Fusion Reports Second Quarter 2025 Financial Results and Corporate Highlights Three presentations at ADA 2025 highlighted the therapeutic potential of icovamenib across multiple aspects of met
  • GlobeNewswireBiomea Fusion Appoints Julianne Averill to its Board of Directors SAN CARLOS, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea,” “Biomea Fusion” or the “Company”) (Nasdaq: BMEA)